|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Nonsynonymous mutations within the human immunodeficiency virus type 1 p17 gene are clustered to sequences binding to the host human leukocyte antigen class I molecules.
|
9491914 |
1998 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A rapid method for identification of human immunodeficiency virus Type 1 (HIV-1) gag subtypes was developed based on restriction fragment length polymorphism (RFLP) analysis of 400 or 650 bp long polymerase chain reaction (PCR) fragments encompassing the start of the p17 (400 bp) and part of the p24 (650bp) regions.
|
10204696 |
1999 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Persistent antibody responses but declining cytotoxic T-lymphocyte responses to multiple human immunodeficiency virus type 1 antigens in a long-term nonprogressing individual with a defective p17 proviral sequence and no detectable viral RNA expression.
|
9525685 |
1998 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human immunodeficiency virus (HIV) type 1 subtype B sequences (whole envelope and the p17 region of gag) were obtained from peripheral blood mononuclear cell samples collected in 1981 from seven HIV-infected U.S. individuals and in 1982 from one infected Canadian resident.
|
12743293 |
2003 |
|
Leukemogenesis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Recent data highlight the presence, in HIV-1-seropositive patients with lymphoma, of p17 variants (vp17s) endowed with B-cell clonogenicity, suggesting a role of vp17s in lymphomagenesis.
|
28747658 |
2017 |
|
Leukemogenesis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The possible pathogenic involvement of HIV p17 protein variants was investigated in a particularly informative case of HIV-related splenic marginal zone lymphoma, which was negative for oncogenic virus infections, thus allowing us to assess the possible direct contribution of these HIV-encoded proteins to lymphomagenesis.
|
30261551 |
2019 |
|
Leukemogenesis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
These results indicate that EBV infection sensitizes B-lymphocytes to CXCR2-mediated effects of p17 proteins and provide evidence supporting a possible contribution of natural p17 variants to EBV-driven lymphomagenesis in the human immunodeficiency virus setting.
|
25704763 |
2015 |
|
Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Notably, HIV-infected patients with lymphomas, but not those not affected by these tumors, were recently shown to carry HIV p17 protein variants with enhanced B-cell clonogenic activity.
|
26773045 |
2016 |
|
Lymphoma, Non-Hodgkin
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Overall, 17 NHLs (14.5%) were found to have CASP10 mutations, which were identified in the coding regions of the prodomain (n = 3), the p17 large protease subunit (n = 11), and the p12 small protease subunit (n = 3).
|
12010812 |
2002 |
|
Lymphoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
An identical dominant variant p17 sequence, p17-Lyrm, carrying a 117 to 118 Ala-Ala insertion was detected in both plasma and lymphoma tissue.
|
30261551 |
2019 |
|
Malignant neoplasm of stomach
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Overall, three of 99 gastric cancers (3%) were found to have the caspase-10 mutations, which were identified in the coding regions of the death effector domain (codon 147) and the p17 large protease domain (codons 257 and 410), whereas no mutation was detected in caspase-8.
|
11973654 |
2002 |
|
Splenic Marginal Zone B-Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The possible pathogenic involvement of HIV p17 protein variants was investigated in a particularly informative case of HIV-related splenic marginal zone lymphoma, which was negative for oncogenic virus infections, thus allowing us to assess the possible direct contribution of these HIV-encoded proteins to lymphomagenesis.
|
30261551 |
2019 |
|
Adult Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
An identical dominant variant p17 sequence, p17-Lyrm, carrying a 117 to 118 Ala-Ala insertion was detected in both plasma and lymphoma tissue.
|
30261551 |
2019 |
|
Childhood Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
An identical dominant variant p17 sequence, p17-Lyrm, carrying a 117 to 118 Ala-Ala insertion was detected in both plasma and lymphoma tissue.
|
30261551 |
2019 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show here that CTL immunodominance in regions of the human immunodeficiency virus type 1 group-associated antigen proteins p17 and p24 correlated with epitope abundance, which was strongly influenced by proteasomal digestion profiles, affinity for the transporter protein TAP, and trimming mediated by the endoplasmatic reticulum aminopeptidase ERAAP, and was moderately influenced by HLA affinity.
|
19412183 |
2009 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Initial studies demonstrated that only 4 of 11 patients recognized the putative immunodominant HLA-A2-restricted p17 epitope SLYNTVATL, suggesting that the remaining subjects might lack significant HIV-specific CD8(+) T-cell responses.
|
10982361 |
2000 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic analysis of the HIV-1 p17 coding region of gag and the C2V5 region of env to determine the genetic relatedness of virus from the donor and recipients; reactivity in quantitative and qualitative assays, and reactivity in donor screening HIV NAT assays in single donation and minipool screening contexts.
|
10889595 |
2000 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Different patterns of temporal evolution in human immunodeficiency virus type 1 V3 and p17 regions are described for eight patients studied during the first years following primary infection.
|
10364382 |
1999 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western immunoblot analysis showed Gag proteins, precursor p55, and cleavage products p24 and p17 in HIV-1-infected tissues.
|
2016757 |
1991 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several HIV-1 CD8(+) T cell escape variants were identified within maternal plasma viral p17 and p24 sequences that were either not detected or did not persist in the plasma of their non-HLA-matched HIV-1-infected infants.
|
18177249 |
2008 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that EBV infection sensitizes B-lymphocytes to CXCR2-mediated effects of p17 proteins and provide evidence supporting a possible contribution of natural p17 variants to EBV-driven lymphomagenesis in the human immunodeficiency virus setting.
|
25704763 |
2015 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
A second larger section covers the latest developments concerning nanomaterial-based biosensors for HIV diagnosis, with paying a special attention to the determination of CD4<sup>+</sup> cells as a hall mark of HIV infection, HIV gene, HIV p24 core protein, HIV p17 peptide, HIV-1 virus-like particles (VLPs) and HIV related enzymes, particularly those that are passed on from the virus to the CD<sup>4+</sup> T lymphocytes and are necessary for viral reproduction within the host cell.
|
31514868 |
2020 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gag p17 matrix sequences of human immunodeficiency virus type 1 (HIV-1) were analyzed from three nontransmitting mothers (mothers who failed to transmit HIV-1 to their infants in the absence of antiretroviral therapy), including multiple deliveries in the case of mother 3.
|
11779356 |
2001 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The gag p17 matrix sequences of human immunodeficiency virus type 1 (HIV-1) from seven infected mother-infant pairs were analyzed after perinatal transmission.
|
10408724 |
1999 |